{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:13:52Z","timestamp":1763018032104},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Most patients with aggressive non-Hodgkin lymphoma will be cured with initial chemoimmunotherapy; however, most patients with relapsed disease will not be cured and will die as a result of their disease. In these cases, continued treatment with conventional chemotherapy is typically not of benefit and can contribute to significant toxicities and decreased quality of life for patients. Fortunately, a number of therapies are currently available or under investigation for this group of patients, ranging from oral tyrosine kinase inhibitors targeting multiple pathways within the malignant cells to adoptive cellular therapies that harness the patient\u2019s immune system to fight disease. Additionally, many agents that are modestly effective as monotherapies can be safely combined with additional novel and conventional therapies to improve response rates and duration. Chimeric antigen receptor T cells are among the most promising group of therapies and provide the potential for cure for patients with relapsed\/refractory lymphoma. In this chapter, we will review the currently available novel treatments as well as those still under investigation and discuss the most appropriate approach to patients with relapsed\/refractory aggressive lymphoma. We will highlight the challenges associated with these therapies, as well as potential toxicities, and the need for additional clinical trials evaluating combinations and newer treatments.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.75","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:59Z","timestamp":1555438439000},"page":"75-82","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Novel therapies for relapsed\/refractory aggressive lymphomas"],"prefix":"10.1182","volume":"2018","author":[{"given":"Jonathon B.","family":"Cohen","sequence":"first","affiliation":[{"name":"Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111520381947300_B1","article-title":"Genomics of aggressive B-cell lymphoma","volume":"2018","author":"Rosenthal","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2019111520381947300_B2","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2019111520381947300_B3","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in patients with double hit lymphoma: a large multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"6769","key":"2019111520381947300_B4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"14","key":"2019111520381947300_B5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"27","key":"2019111520381947300_B6","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111520381947300_B7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2019111520381947300_B8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111520381947300_B9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111520381947300_B10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111520381947300_B11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"12","key":"2019111520381947300_B12","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3324\/haematol.2017.169656","article-title":"Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","author":"Younes","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2019111520381947300_B13","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3324\/haematol.2017.172882","article-title":"CUDC-907 in relapsed\/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial","volume":"102","author":"Oki","year":"2017","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2019111520381947300_B14","article-title":"Objective responses achieved in patients with MYC-altered relapsed\/refractory diffuse large B-cell lymphoma treated with the dual PI3K and HDAC inhibitor CUDC-907 [abstract]","volume":"130","author":"Landsburg","year":"2017","journal-title":"Blood"},{"key":"2019111520381947300_B15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2015.10.005","article-title":"A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","volume":"54","author":"Flinn","year":"2016","journal-title":"Eur J Cancer"},{"issue":"31","key":"2019111520381947300_B16","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin\u2019s lymphoma subtypes: the University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111520381947300_B17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"issue":"13","key":"2019111520381947300_B18","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2016-09-736892","article-title":"Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma","volume":"129","author":"Gayle","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520381947300_B19","article-title":"Phase 1 clinical safety, pharmacokinetics (PK), and activity of apilimod dimesylate (LAM-002A), a first-in-class inhibitor of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), in patients with relapsed or refractory B-cell malignancies [abstract]","volume":"130","author":"Harb","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2019111520381947300_B20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111520381947300_B21","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"issue":"31","key":"2019111520381947300_B22","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111520381947300_B23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br J Haematol"},{"issue":"suppl 2","key":"2019111520381947300_B24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/hon.2438_137","article-title":"Combination of TGR-1202, ublituximab, and bendamustine is safe and highly active in patients with advanced DLBCL and follicular lymphoma [abstract]","volume":"35","author":"Lunning","year":"2017","journal-title":"Hematol Oncol"},{"issue":"5","key":"2019111520381947300_B25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2019111520381947300_B26","article-title":"Single-arm phase II study of MOR208 combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: L-Mind [abstract]","volume":"130","author":"Salles","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2019111520381947300_B27","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111520381947300_B28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2019111520381947300_B29","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111520381947300_B30","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111520381947300_B31","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2019111520381947300_B32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.104.104","article-title":"Results of an ongoing phase 2 study of brentuximab vedotin with Rchp as frontline therapy in patients with high-intermediate\/high-risk diffuse large B cell lymphoma (DLBCL) [abstract]","volume":"128","author":"Budde","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520381947300_B33","article-title":"Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: results from a randomized phase 2 study [abstract]","volume":"130","author":"Sehn","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2019111520381947300_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.182.182","article-title":"A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in relapsed\/refactory B-lineage non-Hodgkin lymphoma","volume":"126","author":"Moskowitz","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520381947300_B35","article-title":"Encouraging early results from the first in-human clinical trial of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory B-cell lineage non-Hodgkin lymphoma [abstract]","volume":"130","author":"Kahl","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111520381947300_B36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2018018531","article-title":"Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2019111520381947300_B37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111520381947300_B38","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111520381947300_B39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"26","key":"2019111520381947300_B40","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111520381947300_B41","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2019111520381947300_B42","article-title":"Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma [abstract]","volume":"130","author":"Schuster","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520381947300_B43","article-title":"High durable CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort [abstract]","volume":"130","author":"Abramson","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520381947300_B44","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL) [abstract]","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520381947300_B45","article-title":"ACTR087, autologous T lymphocytes expressing antibody coupled T-cell receptors (ACTR), induces complete responses in patients with relapsed or refractory CD20-positive B-cell lymphoma, in combination with rituximab [abstract]","volume":"130","author":"Akard","year":"2017","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111520381947300_B46","article-title":"Phase I\/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed\/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma [abstract]","volume":"35","author":"Batlevi","year":"2017","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2019111520381947300_B47","article-title":"Safety and activity of the highly specific BTK inhibitor BGB-3111 in patients with indolent and aggressive non Hodgkin\u2019s lymphoma [abstract]","volume":"130","author":"Tam","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2019111520381947300_B48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1718.1718","article-title":"An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma [abstract]","volume":"124","author":"Younes","year":"2014","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111520381947300_B49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hon.2437_101","article-title":"Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL [abstract]","volume":"35","author":"Nastoupil","year":"2017","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2019111520381947300_B50","article-title":"Phase 1 study of TAK-659, an investigational reversible dual SYK\/FLT-3 inhibitor, in patients (Pts) with lymphoma: updated results from dose-escalation and expansion cohorts [abstract]","volume":"130","author":"Kaplan","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520381947300_B51","article-title":"A phase II study to determine the safety and efficacy of the dual m-TORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed\/refractory diffuse large B cell lymphoma (DLBCL) [abstract]","volume":"130","author":"Eyre","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111520381947300_B52","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111520381947300_B53","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/75\/1252201\/hem01810.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/75\/1252201\/hem01810.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T14:48:07Z","timestamp":1574520487000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/75\/277575\/Novel-therapies-for-relapsedrefractory-aggressive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.75","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}